Related references
Note: Only part of the references are listed.
Article
Immunology
Chanu Rhee et al.
Summary: SARS-CoV-2 is most contagious around symptom onset, with infectivity rapidly decreasing to near-zero afterwards; mild-moderately ill patients can safely discontinue isolation after about 10 days, while severely-critically ill and immunocompromised patients may need 15 days. The longest duration associated with replication-competent virus is 20 days.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Immunology
Ji Hoon Baang et al.
Summary: This case illustrates challenges in managing immunocompromised hosts with chronic COVID-19, who may act as persistent shedders and sources of transmission. The patient's lack of seroconversion and prolonged course highlight the importance of humoral immunity in resolving viral infections.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Infectious Diseases
Yukiko Nakajima et al.
Summary: A COVID-19 case with advanced malignant lymphoma and chemotherapy experienced prolonged viral shedding for 2 months, eventually being discharged with negative PCR results on Day 69. Immunocompromised status may prolong viral shedding, highlighting the importance for clinicians to consider this factor.
JOURNAL OF INFECTION AND CHEMOTHERAPY
(2021)
Article
Immunology
Hassan Tarhini et al.
Summary: This study describes the clinical evolutions and viral mutations of 3 deeply immunocompromised patients, revealing prolonged infectious viral shedding in some cases. Understanding the mechanisms and frequency of prolonged infectiousness is crucial for optimizing isolation policies.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Hematology
Remy Dulery et al.
Summary: Age >= 70 years, relapsed/refractory lymphoma, and recent administration of anti-CD20 therapy are risk factors for prolonged length of in-hospital stay and death for lymphoma patients hospitalized for Covid-19.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Oncology
Nicola Giesen et al.
Summary: The global spread of SARS-CoV-2 and COVID-19 presents unique challenges to medical staff, patients, and their families, particularly for cancer patients. This concise update provides evidence-based recommendations for rapid diagnostics, viral shedding, vaccination, and therapy of COVID-19 in cancer patients, aiming to improve clinical management for this specific population.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Medicine, General & Internal
Brian T. Garibaldi et al.
Summary: This comparative effectiveness research study showed that the receipt of remdesivir was associated with faster clinical improvement in a cohort of predominantly non-White patients with COVID-19. Additionally, the combination of remdesivir and corticosteroids did not reduce the time to death compared with remdesivir administered alone.
Article
Oncology
Astha Thakkar et al.
Summary: The study found differential rates of SARS-CoV-2 IgG seroconversion in cancer patients based on specific cancer types and therapy modalities. Patients with hematological malignancies, those receiving anti-CD-20 antibody therapy, and stem cell transplant patients had significantly lower seroconversion rates, while patients receiving immunotherapy, especially anti-PD-1/PD-L1 monoclonal antibodies, showed 100% seroconversion rates. These findings have implications for clinical monitoring and vaccination strategies to combat the COVID-19 pandemic.
Article
Hematology
Isabel Regalado-Artamendi et al.
Summary: This study examined the impact of COVID-19 on patients with lymphoma, finding that factors like age, confusion, urea concentration, and respiratory rate, as well as active disease, were associated with higher mortality risk. Additionally, continued presence of the virus after week six significantly increased mortality rates.
Review
Medicine, General & Internal
Kelly Ansems et al.
Summary: The results from five randomized controlled trials suggest that remdesivir has little or no effect on all-cause mortality at up to 28 days among hospitalized adults with SARS-CoV-2 infection. Uncertainty remains regarding the effects of remdesivir on clinical improvement and worsening. Future studies should provide more data to draw more reliable conclusions about the potential benefits and harms of remdesivir.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Review
Oncology
Anat Gafter-Gvili et al.
LEUKEMIA & LYMPHOMA
(2016)
